It is fair to say that the ASX has taken a major hit this month. But here's the thing: markets don't fall forever — and when the rebound comes, it tends to reward those who stayed calm and acted early.
Rather than trying to call the bottom, I'm focused on identifying businesses that I believe will come out stronger on the other side. These are companies with world-class leadership, strong balance sheets, and the kind of resilience that lets them keep delivering no matter what the market throws at them.
In addition, brokers have named them as buys recently and are tipping big returns over the next 12 months. Here are three ASX shares I'd be buying before the rebound:
There's a reason CSL has been a favourite among long-term investors for decades: it is one of the few true global biotech leaders on the ASX. But after an extended period of underperformance, sentiment has turned — and CSL is trading well below its historical valuation multiples.
Nevertheless, the company's fundamentals remain incredibly strong. Its core plasma business has recovered and is on course for strong growth in the coming years and its R&D pipeline is packed with high-potential therapies.
With healthcare demand growing globally and biotech innovation accelerating, CSL is a long-term earnings machine trading at a rare discount. That's the kind of mismatch I like to take advantage of.
Goldman Sachs currently rates CSL as a buy with a $307.30 price target.
In a market dominated by short-term noise, Goodman plays the long game — and plays it well. This is no ordinary property stock. Goodman owns and develops high-end logistics, warehousing, and data centre infrastructure for some of the world's biggest and most forward-thinking companies.
Think Amazon. Think next-generation industrial hubs.
What makes Goodman different is its combination of capital discipline, development smarts, and exposure to powerful themes like e-commerce, AI, and data infrastructure.
As the ASX stabilises and ASX growth shares come back into focus, I suspect Goodman could be one to lead the charge.
This week, Morgans upgraded its shares to an add rating with a $35.30 price target.
Finally, Pro Medicus has never been the cheapest share on the ASX — and with good reason. Its health imaging software is used by leading hospitals around the world, and its contracts stretch out years into the future, locking in high-margin recurring revenue.
But with its shares getting caught up in the tech selloff, I see a compelling opportunity for investors. Especially given how the company continues to win major contracts and its platform is becoming increasingly entrenched in the global healthcare system.
Pro Medicus isn't just growing — it is compounding. And for investors who understand the power of long-term recurring revenue, this kind of business is hard to beat.
Goldman Sachs is also a big fan of this ASX share. The broker has a buy rating and $307.00 price target on it shares.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.